Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21483679 | 0.87 | LTA4H (0.57) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL100184 | 0.87 | HRH3 (0.53) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL4939834 | 0.86 | LTA4H (0.56) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL11366627 | 0.85 | LTA4H (0.58) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL3162199 | 0.83 | LTA4H (0.59) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL28934486 | 0.83 | LTA4H (0.65) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL18804815 | 0.82 | MEN1 (0.56) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL30101910 | 0.82 | ALDH1A1 (0.65) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL962262 | 0.81 | HRH3 (0.55) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL4870501 | 0.81 | LTA4H (0.62) | MEN1USP2ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894059-B1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. (BE) | 2005-05-17 | — | — | US | disclosed |
| EP-1165533-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB SA (BE) | 2004-10-13 | — | — | EP | disclosed |
| US-6797713-B2 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. (BE) | 2004-09-28 | — | — | US | disclosed |
| EP-1418173-A1 | N-(3-butyn-1-yl) N-hydroxyurea | UCB, S.A. (BE) | 2004-05-12 | — | — | EP | disclosed |
| US-6686502-B1 | N-HYDROXYL-N-(3-BUTYNYL)-UREA CHEMICAL INTERMEDIATE FOR PIPERIDINE OR PIPERAZINE DERIVATIVES | UCB S.A. (BE) | 2004-02-03 | — | — | US | disclosed |
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6451801-B1 | 1,4-SUBSTITUTED PIPERIDINES AND PIPERAZINES | UCB, S.A. (BE) | 2002-09-17 | — | — | US | disclosed |
| EP-1165533-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058295-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | MEN1 2857/4885USP2 3289/4885ALDH1A1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.